Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): A randomized, double-blinded, multicenter, Phase 2 study
Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): A randomized, double-blinded, multicenter, Phase 2 study
Hajira B. Koeller, Chantal Petit, Surinder Singh Birring, Eva M. Carmona Porquera et al.
Journal
European Respiratory Journal
Topics
Sarcoidosis and Beryllium Toxicity Research
article
Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): A randomized, double-blinded, multicenter, Phase 2 study
Hajira B. Koeller, Chantal Petit, Surinder Singh Birring, Eva M. Carmona Porquera, Theodore F. Reiss, Sibel Atis, Jill Denning, Robert p Baughman, Rohit Gupta, Julien Guiot, Simon p Hart, Bernt Van Den Blink, On behalf of the RESOLVE-Lung investigators, Nesrin Mogulkoc, Min Lin, Marlies Wijsenbeek-Lourens, Natasha Arocho
article en
Abstract
No abstract available for this paper.
Publication Tag
European Respiratory Journal
Institutions
Mayo Clinic (US), University of Liège (BE), King's College London (GB), University of Hull (GB), Erasmus MC (NL), Ege University (TR), Centre Hospitalier Universitaire de Liège (BE), Adjuvance (United States) (US), Roivant Sciences (United States) (US), Mersin Üniversitesi (TR), Covance (United States) (US), University of Cincinnati (US), Hull York Medical School (GB), Temple University (US)